Hello. Can you hear me? Yes. We can hear you well. Okay. Perfect. Yeah. Thank you for taking my questions. So so the first question is on the Lacambi auto injector pen. So a couple days ago, your customer mentioned this product being being prepared for for launch. We believe the USCF FDA should approve the Lacanbi auto injector by the end of this month. Right? Could you give us some color about what preparation you are making for this pan? On slide number eight, you mentioned there is a there is a temporary delay in some products. I just wanna make sure that I just wanna understand whether that's that seller can be. So thank you very much for your question. So what we are doing for the preparation on our side is really to make sure that we can provide as a supplier for the materials and the CDMO business. It's more about making sure we can ramp up the productions, make sure that all the logistics arrangements are put in place. And those are sort of the key activities that we are taking for the launch of the Kenbi. In terms of the delayed products, it is not the Kenbi product that you've mentioned. It's really more about the other products that we have been shifting that did shift from a calendar point of view when we compare to year on year basis. Okay. Very good. Another question is that relates to a slide number seven, the cardiovascular business. You so on on on this slide, you had volume growth as well as price increases for for thermal intervention systems, which is the biggest growth driver. You had both volume growth as well as price increases. Could you help me understand what are the relative contribution from volume versus price? So I think it's the impact of the price is quite smaller. Excuse me, it's the other way around. So what we are considering is that the about two thirds of the impact of the growth is coming from the volume increase. One third is the result of the pricing increase that we have seen is sort of the rough differentiation of the price and the volume increase. Do you think such a price increase would be sustainable? So we've actually had this built into our contract. So the price increase compared to the last fiscal year is we would assume is already kind of quite positive that we can achieve this. The volume is where we would probably see some ups and downs going forward. But like I've mentioned before, we do feel that the increase in the especially in the TIS business in The U. S. Is going to be very strong. Okay. This would be my last one. So just just below the the TIS, right, you see Terremon Neuro. So in China, the sales channel expanded with a VBP resulting in a significant increase. Right? So typically in China, when you have VBP, the sales declines dramatically. So can you explain what happened here? So in terms of the neuro products in China, when VBP was introduced for this area, we actually had a lower market share compared to the current situation. So what took place is that since VBP also determines not just price, but also the volume commitment, we were able to take advantage of that volume commitment and increase our prices into China for the noodle products. Okay, understood. Okay. That's all from me for now. I'll get back into the queue. Thank you. Hi, there. Yeah. Maybe just a quick follow-up question on slide number 15 here. You have on slide number 15, have the second last row, you have lost compensation from a pharmaceutical company, 3,200,000,000.0. Just wanted to get some color on that one. Is that related to the German plan that you acquired from WuXi or is that related to the biosimilar product? So thank you for your question. So this is not related to any of the newly acquired Wuxi plant. This actually relates to the impact that we booked in Q4 when we canceled the project for some of the activities with the pharmaceutical companies. So this is we've continued the negotiations with the pharmaceutical companies. So there is some compensation for the write off or the impairment that we have booked in Q4. So it's relatively more of a relationship towards the Q4 activity in last year that has we've been come to an agreement with the pharmaceutical company in this quarter. So you will pay the so you will pay them 3,200,000,000.0? No. It's the other way around. So so we booked the impairment in q four last year, so they are compensating for that impact that we put Okay. In Understood. Yes, understood. Okay. So they are paying you. Okay, great. Thank you.